natgillin/translations-raw huggingface dataset:
Hypotension, hypertension, hot flushes, flushing, peripheral coldness
hipotenzija, hipertenzija, vročinski oblivi, pordevanje, hladne okončine
Hypotension, hypertension, hot flushes, flushing, peripheral coldness
hipotenzija, hipertenzija,vročinski oblivi, pordevanje, hladne okončine
Hypotension, hypertension, vein discolouration, vein distended
hipotenzija, hipertenzija, obarvanje ven, razširitev ven
Hypotension, hypertension, vein discolouration, vein distended
hipotenzija, hipertenzija, vensko razbarvanje, razširitev ven
hypotension, orthostatic hypotension
hipotenzija, ortostatska
hypotension, orthostatic hypotension
hipotenzija, ortostatska hipotenzija
hypotension, orthostatic hypotension, flushing
hipotenzija, ortostatska hipotenzija, rdečica
hypotension, orthostatic hypotension, flushing
hipotenzija, ortostatska hipotenzija, vročinski oblivi
Hypotension, orthostatic hypotension, flushing, hypertension, phlebitis
hipotenzija, ortostatska hipotenzija, zariplost, hipertenzija, flebitis
Hypotension, pallor, peripheral coldness
hipotenzija, bledica, mrzle okončine
hypotension, raynaud’s phenomenon, cold hands and feet
hipotenzija, Raynaudov fenomen, mrzle dlani in stopala
hypotension, Raynaud’s phenomenon, cold hands and feet.
hipotenzija, Raynaudov fenomen, mrzle dlani in stopala
hypotension, syncope paralysis (Bell’s palsy), neuropathy, neuritis (including Guillain Barre Syndrome, myelitis including transverse myelitis), encephalitis, optical neuritis. lymphadenopathy.
hipotenzija, sinkopa; paraliza (Bellova paraliza), nevropatija, nevritis (vključno z Guillain-Barréjevim sindromom, mielitis, vključno s transverznim mielitisom), encefalitis, optični nevritis; limfadenopatija.
hypotension, syncope, visual
Kortikosteroidi
hypotension, syncope, visual changes
intenzivno nego (EIN) ali podobnem
Hypotension, Vasculitis
hipotenzija, vaskulitis
hypotension, visual changes and
spremembe vida in priapizem.
Hypotension1, 4
hipotenzija1, 4
Hypotension1,4
hipotenzija1, 4
Hypotension2, orthostatic hypotension
hipotenzija, ortostatska hipotenzija
Hypotension; Hypertension Haemorrhage
hipotenzija, hipertenzija, krvavitev
Hypotension; Hypertension; Haemorrhage
hipertenzija, krvavitev
Hypotension; Hypertension; Haemorrhage
hipotenzija, hipertenzija, krvavitev
Hypotension; thrombophlebitis; flushing
hipotenzija; tromboflebitis; vročinski oblivi
Hypotensiona,b, d
hipotenzijaa, b,d
Hypotensionc,a
hipotenzijac,a
Hypotensionh
hipotenzijah
Hypothermia
Občasni
Hypothermia
osip, plešavost
hypothermia, chills, body temperature increased, thirst, drug withdrawal
hipotermija, mrazenje, zvišana telesna temperatura, žeja, sindrom odtegnitve zdravila, absces na mestu injiciranja, celulitis na mestu
Hypothermia12
hipotermija
Hypothermia12
poglavje 4.4)11
hypothermiac, body temperature decreasedc, drug withdrawal syndromec, indurationc
hipotermijac, znižana telesna temperaturac, induracijac,sindrom odtegnitve zdravilac, otrdelostc
Hypothyroidis m, hyperthyroidi sm
hipotiroidizem, hipertiroidizem
Hypothyroidism
pogosti
hypothyroidism (myxoedema)
hipotiroidizem (miksedem)
Hypothyroidism Blood thyroid stimulating hormone increased‡
hipotiroidizem zvišan tirotropni hormon v krvi
Hypothyroidism has been observed to occur early as well as late during treatment with sunitinib.
Opažali so, da se je hipotiroidizem pojavljal v zgodnjem in tudi poznejšem obdobju zdravljenja s sunitinibom.
Hypothyroidism in HIV co-infected patients is a very common event and occur in ≥1/10 subjects, particularly when PAS is administered with ethionamide/prothionamide.
Hipotiroidizem pri z virusom HIV sočasno okuženih bolnikih je zelo pogost; pojavi se pri ≥1/10 bolnikih, predvsem pri bolnikih, ki prejemajo PAS skupaj z etionamidom/protionamidom.
Hypothyroidism occurred in 237 (8.5%) patients, including Grade 2 or 3 cases in 174 (6.2%) and 3 (0.1%) patients, receiving pembrolizumab.
Hipotiroidizem se je pojavil pri 237 bolnikih (8,5 %), ki so prejemali pembrolizumab; pri 174 bolnikih (6,2 %) je bil 2. stopnje in pri 3 bolnikih (0,1 %) 3. stopnje.
Hypothyroidism resolved in 48 (20%) patients.
Hipotiroidizem je izzvenel pri 48 bolnikih (20 %).
Hypothyroidism was reported as an adverse reaction in 7 patients (4%) receiving sunitinib across the two cytokine-refractory MRCC studies; in 61 patients (16%) on sunitinib and three patients (<1%) in the IFN- arm in the treatment-naïve MRCC study.
V dveh študijah MRCC, odpornega proti citokinom, so hipotiroidizem kot neželeni učinek opisali pri 7 bolnikih (4 %), ki so prejemali sunitinib; v študiji še nezdravljenega MRCC pa pri 61 bolnikih (16 %) v skupini s sunitinibom in pri 3 bolnikih (< 1 %) v skupini z IFN-.
hypothyroidism*
Hipotiroidizem
hypothyroidism, hyperthyroidism, hyperglycaemiab
hipotiroidizem, hipertiroidizem, hiperglikemijab
hypothyroidism, increased blood thyroid stimulating hormone
hipotiroidizem, povišana koncentracija tirotropina v krvi
Hypothyroidism§, Hyperthyroidism§, virilism
hipotiroidizem§ hipertiroidizem§, virilizem
Hypotonia
hipotonija
Hypotonic reactions or hypotonic-hyporesponsive episodes (HHE)
hipotonične reakcije ali hipotonično- hiporesponzivna epizoda (HHE)
Hypotonic-hyporesponsive episode
hipotonično-hiporesponzivne epizode
Hypotonic-hyporesponsive episode (collapse or shock-like state)
epizoda hipotonije in zmanjšane odzivnosti (kolaps ali šoku podobno stanje)
Hypovolaemic hyponatraemia
hipovolemična hiponatriemija
Hypoxia Wheezing Dyspnoea
hipoksija sopenje dispneja
Hypoxia, cough, dyspnoea
hipoksija, kašelj, dispneja
Hypoxia, tachypnoea, bronchospasm, cough
hipoksija, tahipneja bronhospazem, kašelj
Hypromellose 2208
hipromeloza 2208,
hypromellose 2910, sodium citrate dihydrate,
hipromeloza 2910, natrijev citrat dihidrat,
Hypromellose 6cP Titanium dioxide (E171) Lactose monohydrate Macrogol 3350 Triacetin
hipromeloza 6cP titanov dioksid (E171)laktoza monohidrat makrogol 3350 triacetin
hypromellose acetate succinate
hipromeloza acetat sukcinat brezvodni kalcijev hidrogenfosfat mikrokristalna celuloza
Hypromellose acetate succinate Sucrose
hipromeloza acetat sukcinat saharoza
Hypromellose acetate succinate, medium grade Lactose monohydrate
hipromeloza acetat sukcinat, srednje stopnje laktoza monohidrat
Hypromellose Microcrystalline cellulose Mannitol
hipromeloza mikrokristalna celuloza manitol
Hypromellose Talc
Hipromeloza Smukec
Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide black (E172), iron oxide red (E172), carnauba wax.
hipromeloza propilenglikol titanov dioksid (E171) črni železov oksid (E172) rdeči železov oksid (E172) karnavbov vosek
Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide black (E172), iron oxide red (E172), iron oxide yellow (E172), carnauba wax.
hipromeloza propilenglikol titanov dioksid (E171) črni železov oksid (E172) rdeči železov oksid (E172) rumeni železov oksid (E172) karnavbov vosek
Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide red (E172), carnauba wax.
hipromeloza propilenglikol titanov dioksid (E171) rdeči železov oksid (E172) karnavbov vosek
Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide red (E172), iron oxide black (E172), carnauba wax.
hipromeloza propilenglikol titanov dioksid (E171) rdeči železov oksid (E172) črni železov oksid (E172) karnavbov vosek
Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide red (E172), iron oxide yellow (E172), carnauba wax.
hipromeloza propilenglikol titanov dioksid (E171) rdeči železov oksid (E172) rumeni železov oksid (E172) karnavbov vosek
Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide yellow (E172), carnauba wax.
hipromeloza propilenglikol titanov dioksid (E171) rumeni železov oksid (E172) karnavbov vosek
Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide yellow (E172), iron oxide black (E172), carnauba wax.
hipromeloza propilenglikol titanov dioksid (E171) rumeni železov oksid (E172) črni železov oksid (E172) karnavbov vosek
Hypromellose.
hipromeloza
HyQvia 100 mg/ml infusion for subcutaneous use Human normal immunoglobulin
HyQvia 100 mg/ml infuzija za subkutano uporabo Humani polispecifični imunoglobulin
HyQvia 100 mg/ml solution for infusion for subcutaneous use Human normal immunoglobulin
HyQvia 100 mg/ml raztopina za infundiranje za subkutano uporabo Humani polispecifični imunoglobulin
HyQvia administration scheme
Shema uporabe zdravila HyQvia
HyQvia is a dual vial unit containing: a solution of recombinant human hyaluronidase (Step 1 of HyQvia/Infuse first) and a solution of human normal immunoglobulin 10% (Step 2 of HyQvia/Infuse second).
Zdravilo HyQvia je enota z dvema vialama, ki vsebujeta: raztopino rekombinantne humane hialuronidaze (1. korak zdravila HyQvia/infundirajte kot prvo komponento) in raztopino humanega polispecifičnega imunoglobulin 10 % (2. korak zdravila HyQvia/infundirajte kot drugo komponento).
HyQvia is supplied as a pack containing:
Zdravilo HyQvia je na voljo v pakiranju, ki vsebuje:
HyQvia is used as ‘replacement therapy’ to treat: primary immunodeficiency syndromes (PID, when patients are born with an inability to produce enough antibodies); low levels of antibodies in the blood in patients who have chronic lymphocytic leukaemia or myeloma (two cancers affecting different types of white blood cell) and who have frequent infections.
Zdravilo HyQvia se uporablja kot „nadomestno zdravljenje‟ pri: sindromih primarne imunske pomanjkljivosti (PID, pri bolnikih s prirojeno nezmožnostjo tvorjenja zadostnega števila protiteles); nizkih ravneh protiteles v krvi pri bolnikih s kronično limfocitno levkemijo ali mielomom (dvema vrstama raka, ki prizadeneta različne vrste belih krvnih celic), ki so dovzetni za pogoste okužbe.
HyQvia Median (95% Cl)
HyQvia Mediana (95-odstotni IZ)
HZC102970 and
HZC102970 in HZC102871
Hôpital Xavier Arnozan Avenue du Haut Lévèque 33600 Pessac (Bordeaux) France
Hôpital Xavier Arnozan Avenue du Haut Lévèque 33600 Pessac (Bordeaux) Francija
i 48 weeks of double-blind adefovir dipivoxil followed by 144 weeks open-label tenofovir disoproxil fumarate.
i 48-tedensko dvojno slepo zdravljenje z dipivoksiladefoviratom, ki mu sledi 144-tedensko odprto zdravljenje z dizoproksiltenofovirijevim fumaratom.
i 48 weeks of double-blind tenofovir disoproxil fumarate followed by 192 weeks open-label.
i 48-tedensko dvojno slepo zdravljenje z dizoproksiltenofovirijevim fumaratom, ki mu sledi 192-tedensko odprto zdravljenje.
I am on Lysodren (mitotane) treatment
Zdravim se z zdravilom Lysodren (mitotanom)
I am prone to acute adrenal insufficiency In case I need emergency care, adequate precautionary measures should be taken
Nagnjen sem k akutni insuficienci nadledvične
I don’t know how to do a subcutaneous injection.
Ne znam izvesti subkutanega injiciranja.
i e.g. haemarthrosis, muscle haemorrhage
i npr. hemartroza, krvavitev v mišice
i Fluid overload, fluid retention, gastrointestinal oedema, generalised oedema, oedema, oedema due to cardiac disease, perinephric effusion, post procedural oedema, visceral oedema. j Genital swelling, incision site oedema, oedema genital, penile oedema, penile swelling, scrotal oedema, skin swelling, testicular swelling, vulvovaginal swelling.
j Oteklina genitalij, edem na mestu kirurškega reza, genitalni edem, edem penisa, oteklina penisa, edem modnika, otekanje kože, otekanje mod, otekanje vulve in vagine.
I heard more than two clicks during my injection - two louder clicks and a soft one.
Med injiciranjem sem slišal/a več kot dva klika – dva glasnejša klika in enega tišjega.
I Interferon alfa-2b 3 MIU
I Interferon alfa-2b 3 mio i.e.
I IntronA (3 MIU 3 times a week)
I IntronA (3 mio i.e. trikrat na teden)
I n cases where a more rapid response is required your doctor may prescribe a dose of 160 mg at week 0 (as 4 injections in one day or 2 injections per day for two consecutive days), 80 mg (2 injections) at week 2, and thereafter as 40 mg (1 injection) every other week.
Kadar je potreben hitrejši odziv, vam zdravnik lahko predpiše odmerek 160 mg 0. teden (v 4 injekcijah na en dan ali v 2 injekcijah dva dni zapored), 80 mg (2 injekciji) 2. teden in potem 40 mg (1 injekcija) vsak drugi teden.
I Viraferon (3 MIU 3 times a week)
I Viraferon (3 mio i.e. trikrat na teden)
I-10044 Pianezza Italy
B-1420 Braine l’Alleud I-10044 Pianezza
I-20122 Milan Italy
I-20122 Milan Italija
I-21040 Origgio / VA Tel: + 39 02 96541
Tel: + 39 02 96541
I-36100 Vicenza(VI) - Italy
I-36100 Vicenza(VI) – Italija
I-43056 San Polo di Torrile Parma
43056 San Polo di Torrile Parma
I-80058 Torre Annunziata - Napoli Italy
I-80058 Torre Annunziata - Neapelj Italija
I-Neb AAD nebuliser (1 ml ampoule with white and yellow rings)
Nebulator I-Neb AAD (1-mililitrska ampula z belim in rumenim obročem)
I-Neb AAD nebuliser:
Nebulator I-Neb AAD
I-Neb nebuliser
Nebulator I-Neb
I. Blood glucose concentrations following a single pre-meal dose of NovoRapid injected immediately before a meal (solid curve) or soluble human insulin administered 30 minutes before a meal (hatched curve) in patients with type 1 diabetes mellitus.
Koncentracija glukoze v krvi po enem odmerku zdravila NovoRapid, injiciranem tik pred obrokom (neprekinjena krivulja) in topnega humanega insulina, apliciranega 30 minut pred obrokom (pikčasta krivulja) pri bolnikih s sladkorno boleznijo tipa 1.
I.M.
I. M.
I.M. or S.C. injection
i.m. ali s.c.
I.M. or S.C. injection of 0.25, 0.5 ml or 1 ml, depending on the age and species.
i.m. ali s.c. odmerek po 0,25, 0,5 ml ali 1 ml, glede na starost in živalsko vrsto.
i.m. use
i.m. uporaba
I.V. use
za intravensko uporabo
I.V. use.
intravenska uporaba
I/R IntronA (3 MIU 3 times a week) + ribavirin (1,000/1,200 mg/day)
I/R IntronA (3 mio i.e. trikrat na teden) + ribavirin (1.000/1.200 mg/dan)
I/R Viraferon (3 MIU 3 times a week) + ribavirin (1,000/1,200 mg/day)
I/R Viraferon (3 mio i.e. trikrat na teden) + ribavirin (1.000/1.200 mg/dan)
I384N
C382Y
I407K
H406R
I407V
S405R
I47A and L76V have been observed in rebound isolates with reduced lopinavir susceptibility from patients receiving Kaletra therapy.
Pri izolatih s preobratom, to je z manjšo občutljivostjo za lopinavir pri bolnikih, ki so dobivali zdravilo Kaletra, so opažali tudi mutaciji I47A in L76V.
IAR’s also include atrial fibrillation and anaphylaxis which occur beneath the 0.5% cut for related events (see section 4.4).
Z infuzijo povezane reakcije vključujejo atrijsko fibrilacijo in anafilakso, ki se pojavita pod mejo 0,5 % za povezane pojave (glejte poglavje 4.4).
IAS-USA lists
IAS-USA seznami
Iasibon 1 mg concentrate for solution for infusion
Iasibon 1 mg koncentrat za raztopino za infundiranje
Iasibon 1 mg is supplied as pack containing 1 ampoule (2 ml type I glass ampoule).
Zdravilo Iasibon 1 mg je na voljo v pakiranju po 1 ampula (2 ml ampula iz stekla tipa I).
Iasibon 2 mg concentrate for solution for infusion
Iasibon 2 mg koncentrat za raztopino za infundiranje
Iasibon 2 mg is supplied as pack containing 1 ampoule (4 ml type I glass ampoule).
Zdravilo Iasibon 2 mg je na voljo v škatlah, v katerih je 1 ampula (4 ml ampula iz stekla tipa I).
Iasibon 2mg is supplied as pack containing 1 ampoule (4 ml type I glass ampoule).
Zdravilo Iasibon 2 mg je na voljo v pakiranju po 1 ampula (4 ml ampula iz stekla tipa I).
Iasibon 50 mg film coated tablets
Iasibon 50 mg filmsko obložene tablete
Iasibon 50 mg film coated tablets are supplied in Polyamide/Al/PVC - Aluminum foil blister with 3, 6, 9, 28 or 84 tablets, packaged in a cardboard box.
Filmsko obložene tablete Iasibon 50 mg so pakirane v pretisnih omotih (poliamid/Al/PVC – aluminijasto folija) po 3, 6, 9, 28 ali 84 tablet, na voljo so v škatlah.
Iasibon 6 mg concentrate for solution for infusion
Iasibon 6 mg koncentrat za raztopino za infundiranje
Iasibon can also be prescribed if you have a raised calcium level in your blood due to a tumour.
Zdravilo Iasibon uporabljamo pri odraslih in vam ga bodo predpisali, če imate raka dojke, ki se je razširil na kosti (metastaze v kosteh).
Iasibon concentrate for solution for infusion should be administered as an intravenous infusion.
Koncentrat za raztopino za infundiranje Iasibon damo v obliki intravenske infuzije.
Iasibon contains less than 1 mmol sodium (23 mg) per vial, i.e. essentially sodium free.
Iasibon vsebuje manj kot 1 mmol natrija (23 mg) na ampuli, kar v bistvu pomeni brez natrija.
Iasibon is a colourless, clear solution.
Zdravilo Iasibon je brezbarvna, bistra raztopina.
Iasibon is a ‘generic medicine’.
Zdravilo Iasibon je „generično zdravilo“.
Iasibon is indicated in adults for
Iasibon je indiciran pri odraslih za:
Iasibon is indicated in adults for:
Iasibon je indiciran pri odraslih za:
Iasibon is normally given by a doctor or other medical staff who have experience with the treatment of cancer.
Zdravilo Iasibon običajno aplicira zdravnik ali drugo medicinsko osebje, ki ima izkušnje pri zdravljenju raka..
Iasibon is used in adults and prescribed to you if you have breast cancer that has spread to your bones (called ‘bone metastases’)
Zdravilo Iasibon uporabljamo pri odraslih in vam ga bodo predpisali, če imate raka dojke, ki se je razširil na kosti (metastaze v kosteh).
Iasibon is used in adults and prescribed to you if you have breast cancer that has spread to your bones (called ‘bone metastases’).
Zdravilo Iasibon uporabljamo pri odraslih in vam ga bodo predpisali, če imate raka dojke, ki se je razširil na kosti (metastaze v kosteh).
Iasibon is usually administered in a hospital setting.
Dajanje zdravila Iasibon običajno poteka v bolnišnici.
Iasibon should not be used during breast feeding.
Zdravila Iasibon se ne sme uporabljati med dojenjem.
Iasibon should not be used during breat-feeding.
Zdravila Iasibon se ne sme uporabljati med dojenjem.
Iasibon should not be used in children and adolescents below the age of 18 years.
Zdravilo Iasibon se ne sme uporabljati pri otrocih in mladostnikih, starih manj kot 18 let.
Iasibon should not be used in children and adolescents below the age of 18 years.
Zdravilo Iasibon se ne sme uporabljati pri otrocih in mladostnikih,, starih manj kot 18 let.
Iasibon should not be used in children and adolescentsbelow the age of 18 years.
Zdravilo Iasibon se ne sme uporabljati pri otrocih in mladostnikih, starih manj kot 18 let.
Iasibon therapy should only be initiated by physicians experienced in the treatment of cancer.
Zdravljenje z zdravilom Iasibon lahko vpelje le zdravnik z izkušnjami pri zdravljenju raka.
IBA Molecular Spain, S.A., Madrid, Spain
IBA Molecular Spain, S.A., Madrid, Španija
IBA Molecular Spain, S.A., Seville, Spain
IBA Molecular Spain, S.A., Seville, Španija
Ibaflin 3% Oral Gel
Ibaflin 3 % peroralni gel
Ibaflin 3% oral gel
Ibaflin 3 %, peroralni gel
Ibaflin 3% oral gel for dogs and cats
Ibaflin 3 %, peroralni gel za pse in mačke
Ibaflin 3% oral gel for dogs and cats Ibaflin 7.5% oral gel for dogs
Ibaflin 3 %, peroralni gel za pse in mačke Ibaflin 7,5 %, peroralni gel za pse
Ibaflin 3% oral gel for dogs and cats.
Ibaflin 3 %, peroralni gel za pse in mačke
Ibaflin 3% Oral Gel: 30 mg of ibafloxacin per g of gel (equivalent to 30.9 mg/ml); Ibaflin 7.5% Oral Gel: 75 mg of ibafloxacin per g of gel (equivalent to 78.8 mg/ml)
Ibaflin 3 %, peroralni gel: 30 mg ibafloksacina v 1 g gela (ustreza 30,9 mg/ml) Ibaflin 7,5 %, peroralni gel: 75 mg ibafloksacina v 1 g gela (ustreza 78,8 mg/ml)
Ibaflin 30 mg tablets for dogs Ibaflin 150 mg tablets for dogs Ibaflin 300 mg tablets for dogs Ibaflin 900 mg tablets for dogs
Ibaflin 30 mg, tablete za pse Ibaflin 150 mg, tablete za pse Ibaflin 300 mg, tablete za pse Ibaflin 900 mg, tablete za pse
Ibaflin 7.5% Oral Gel
Ibaflin 7,5 % peroralni gel
Ibaflin 7.5% oral gel
Ibaflin 7,5 %, peroralni gel
Ibaflin 7.5% oral gel for dogs
Ibaflin 7,5 %, peroralni gel za pse
Ibaflin 7.5% oral gel for dogs.
Ibaflin 7,5 %, peroralni gel za pse
Ibaflin 7.5% Oral Gel should not be used in cats.
Ibaflin 7,5 % peroralnega gela ne smemo dajati mačkam.
Ibaflin can be administered at any time of the day without consequences for efficacy.
Ibaflin lahko dajemo ob kateremkoli času dneva, ne da bi se spremenila njegova učinkovitost.
Ibaflin gel contains ibafloxacin as active ingredient.
Zdravilna učinkovina v Ibaflinu je ibafloksacin.
Ibaflin gel is indicated in cats for treatment of the following conditions:
Ibaflin gel je pri mačkah indiciran za zdravljenje naslednjih bolezenskih stanj:
Ibaflin gel should only be used based on susceptibility testing.
Ibaflin uporabljamo na podlagi testiranja občutljivosti povzročitelja.
Ibaflin is indicated for the treatment of the following conditions in dogs:
Ibaflin je pri psih indiciran za zdravljenje naslednjih bolezenskih stanj:
Ibaflin is used to treat the infections in dogs and cats: skin infections, including shallow and deep ‘pyoderma’, infected wounds and abscesses caused by bacteria such as Staphylococci, E. coli, Proteus species and Pasteurella species, upper respiratory tract infections caused by Staphylococci, E. coli and Klebsiella species.
Zdravilo Ibaflin se uporablja za zdravljenje okužb pri psih in mačkah: okužb kože, vključno s površinsko in globoko „piodermijo“, okuženih ran in abscesov, ki jih povzročajo bakterije, kot so na primer Staphylococci, E. coli, Proteus vrste in Pasteurella vrste, okužb zgornjih dihalnih poti, ki jih povzročajo Staphylococci, E. coli in Klebsiella vrste.
Ibaflin oral gel is indicated in dogs for the treatment of skin infections (pyoderma – superficial and deep, wounds, abscesses).
Ibaflin peroralni gel je indiciran pri psih za zdravljenje okužb kože (piodermija – površinska in globoka, rane, abscesi).
Ibaflin should only be used based on susceptibility testing.
Ibaflin smemo uporabljati samo na osnovi testiranja občutljivosti povzročitelja.
Ibaflin should only be used based on susceptibility testing.
Ibaflin uporabljajte samo na podlagi izvidov testiranja občutljivosti povzročitelja.
IBAFLIN TABLETS 30, 150, 300 AND 900 MG
IBAFLIN, TABLETE 30, 150, 300 IN 900 mg
Ibafloxacin
Ibafloksacin
Ibafloxacin 150 mg
Ibafloksacin 150 mg
Ibafloxacin 30 mg
Ibafloksacin 30 mg
Ibafloxacin 300 mg
Ibafloksacin 300 mg
Ibafloxacin 900 mg
Ibafloksacin 900 mg
Ibafloxacin is a broad spectrum antibiotic with bactericidal action resulting from inhibition of bacterial DNA gyrase.
Njegovo delovanje temelji na zaviranju bakterijske DNA-giraze.
Ibafloxacin is a synthetic antimicrobial substance of the fluoroquinolone class.
Ibafloksacin je sintetična protimikrobna učinkovina iz skupine fluorokinolonov.
Ibafloxacin, is an antibiotic belonging to the class ‘fluoroquinolones’.
Ibafloksacin je antibiotik, ki spada v skupino „fluorokinolonov“.
Ibandronate works by reducing the amount of calcium that is lost from your bones.
Zdravilo Iasibon zavira izločanje kalcija iz kosti.
Ibandronatebandro nate 6 mg
Ibandronska kislina 6 mg
Ibandronic acid 150 mg once monthly
Ibandronska kislina v odmerku 150 mg enkrat mesečno
Ibandronic acid 150 mg once monthly (N=320)
ibandronska kislina 150 mg enkrat mesečno (n = 320)
Ibandronic acid 150 mg once monthly was shown to be at least as effective as ibandronic acid 2.5 mg daily at increasing BMD in a two year, double-blind, multicentre study (BM 16549) of postmenopausal women with osteoporosis (lumbar spine BMD T score below -2.5 SD at baseline).
Ibandronska kislina v odmerku 150 mg enkrat mesečno se je v dveletni dvojno slepi, multicentrični študiji (BM 16549) pri ženskah z osteoporozo v postmenopavzi (izhodiščna T-vrednost MKG ledvene hrbtenice pod –2,5 SD) glede povišanja MKG izkazala za najmanj enako učinkovito kakor ibandronska kislina v odmerku 2,5 mg enkrat dnevno.
Ibandronic acid 2.5 mg daily (N=294)
ibandronska kislina 2,5 mg dnevno (n = 294)
Ibandronic acid 3 mg injection every 3 months
Ibandronska kislina 3 mg v obliki injekcije, dane vsake 3 mesece
ibandronic acid 3 mg injection every 3 months (N=365)
ibandronska kislina 3 mg v obliki injekcije vsake 3 mesece